Nvaxlong
NVAX listed on Nasdaq. I bought these shares at the very bottomNVAX listed on Nasdaq. I bought these shares at the very bottom. I made a take profit at the price of 16. Now we have a correction and I expect a drop to the price of 5.05 and there I will buy shares of this company
NVAX Bullish Breakout After Settlement of Gavi DisputeNVAX Technical Analysis
NVAX has been showing some solid bullishness since settling the Gavi dispute. NVAX is pumping out of the buy zone, and there has been a bullish breakout above the light blue resistance line. The key price target ahead is the green resistance line ($6.36), a yellow resistance zone ($8.20 to $8.46), and a red resistance line ($10.23). I have $3.54 to $3.93 as my new buy zone. I think there are likely to be more buy opportunities around there. For now the price is bullish and trending up.
Novavax Reaches Settlement With Gavi, Paving The Way Forward
In a significant development announced on February 22, Novavax, a key player in the COVID-19 vaccine market, has reached a settlement with Gavi, the Vaccine Alliance, resolving a contentious dispute over unfulfilled vaccine orders. This settlement marks a critical juncture for Novavax, alleviating financial uncertainties and setting the stage for future growth and collaborations.
The Dispute Resolution
Novavax has committed to repaying Gavi a minimum of $475 million, either in cash or through vaccine supplies, by the end of 2028. This agreement comes as a resolution to a conflict stemming from Novavax’s inability to deliver on a contract for up to 350 million doses of its COVID-19 vaccine, despite Gavi’s advance payment of $700 million in 2021 and 2022.
Impact On Novavax
The announcement led to a significant surge in Novavax’s stock price, which climbed by 23.2% to $4.91 following the news. This is a noteworthy rebound for the company, whose stock had previously plummeted by nearly 60% amid concerns over its operational viability. The settlement not only removes a major financial overhang but also enhances Novavax’s appeal as a business partner, according to CEO John Jacobs.
Settlement Terms
Under the terms of the settlement, Novavax has made an upfront payment of $75 million to Gavi, with additional payments of $80 million annually in quarterly installments scheduled through 2028. These payments can be adjusted if Gavi opts to receive vaccines instead of cash. The agreement also includes provisions for extra vaccine credits, potentially worth up to $225 million, should demand exceed the annual $80 million mark.
Strategic Implications For Novavax
The resolution of this dispute is pivotal for Novavax, offering a path to stabilize its financials and focus on future endeavors. CEO John Jacobs highlighted the settlement’s role in mitigating the risk of a substantial one-time payment and enabling better cash flow management. The estimated present value of the settlement ranges between $300 and $400 million, signaling a strategic financial recalibration for the company.
Looking Ahead
With new leadership at the helm of both Novavax and Gavi, this agreement signals a fresh start and a mutual focus on future collaborations and initiatives. Novavax is already eyeing new revenue streams, with plans to introduce a combination COVID-flu vaccine by 2026 and capitalize on a malaria vaccine developed in partnership with the Serum Institute of India. These initiatives, coupled with significant cost reductions and operational streamlining, underscore Novavax’s commitment to overcoming past challenges and seizing future opportunities.
Conclusion
In conclusion, the settlement between Novavax and Gavi not only resolves a major dispute but also highlights the resilience and strategic pivoting of Novavax amidst the complexities of the global vaccine landscape. As the company navigates beyond its COVID-centric phase, this development offers promising insights into its potential for innovation, growth, and partnerships in the years to come.
$NVAX Trending Back Down to the Buy ZoneNVAX has started distributing millions of COVID-19 vaccine shots. However, NVAX is trending back down towards the buy zone. I think that this will present a great second chance buy opportunity after NVAX's recent rally to $8. The markets have been affected by the new Israel Palestine conflict. Other key events this week are September PPI inflation data and Fed meeting minutes on Wednesday October 11. I think the markets are likely to have some sideways price action on Tuesday in anticipation of the new inflation and fed data.
Covid & Vaccine Related Novavax Long Play in the cardsHi guys! So lately theres been some buzz on a particular variant, increased cases of hospitalizations and government backing. At risk population that require vaccinations/ boosters will always exist. Therefore, i believe this fact along with various technical analysis findings can make companies such as Biontech, Moderna and even not as famous Novavax potential plays.
(Look below for my analysis on Biontech)
Jumping right in. This is a technical analysis on Novavax (NVAX) on the 3 day timeframe.
Zoomed in we can see that we have a GOLDEN CROSS.
Between the:
21 EMA
50 SMA
Being on the 3 Day its ALOT more Powerful than having it on 1 Day and it may influence the larger timeframes. Which is what we want.
We have also maintained SUPPORT on both Moving Average. (21 EMA and 50 SMA)
This is a great sign, if we continue like how we are with our current candle during the close that would further confirm Support and a bullish case in my opinion.
This 3 day candle will close on the 8th of September. Pay attention to how big the body of candle gets on the close.
With this i would like Volume to start to pick up especially if and when we get to the "flat trendline".
Another important development to notice is the Ascending Triangle.
This can be giving us evidence we are in the process of BOTTOMING out.
Watch for the breakout ABOVE the Flatline. This with confirmation of Support on flatline would be a Major Area to take Long Positions.
I would ADVISE AGAINST buying inside the triangle. But Belowthe Ascending Support Line would be an area for Stop losses.
Watch also how the MACD acts. If we continue in Green and the Blue/Orange lines make it ABOVE 0 level. We will be off to the races, as it would be the necessary catalyst that provides momentum to have the triangle play out.
__________________________________________________________________________________
Thank you for taking the time to read my analysis. Hope it helped keep you informed. Please do support my ideas by boosting, following me and commenting. Thanks again.
Stay tuned for more updates on NVAX in the near future.
If you have any questions, do reach out. Thank you again.
DISCLAIMER: This is not financial advice, i am not a financial advisor. The thoughts expressed in the posts are my opinion and for educational purposes. Do not use my ideas for the basis of your trading strategy, make sure to work out your own strategy and when trading always spend majority of your time on risk management strategy.
$NVAX Key Price Targets After 10%+ Intraday RallyNVAX has been one of our best performing stocks that has been trading in an accumulation range between $7 and $9. I believe that NVAX is trending for an upward breakout in Q4. The FDA has approved NVAX's COVID vaccine for patient ages 12+, and the European Union is set to make a decision in October. I believe that NVAX has promising short-term outlook that will lead to a rally with a break above $9. So far $9.18 has been a key resistance target, but I believe that NVAX will ultimately break out to the light blue resistance level at $16.21
$NVAX Quarter 3 (Q3) AnalysisNVAX has received solid support in the buy zone ($6.50-$7) throughout Q3. I think NVAX will have its breakout in Q4 and the key resistance targets are the $16.21 and $23.13 price levels. October will be an important month for NVAX with the European Union deciding whether to approve the NVAX COVID vaccine. Germany already has an interest in placing an order for 10.6 million vaccine doses in Q4 if NVAX does receive approval.
NVAXNot financial advice.
The essence of investing & trading is the intelligent and patient preying on the greed, fear, impatience, addiction and ignorance of the majority. It's definitionally Darwinian.
NVAX Text book bearish Shark patternHi guys, NVAX showed up on my feed today as down 25% so I decided to take a look. What I see is a text book Bearish Shark attack on the stock. Looking at the embedded image in this chart you can compare the events as they occurred. The stock price has also gone back to beginning of the rally.
Please do your DD this is not a financial advice.
Bullish hammer on Novavax?Novavax
Short Term
We look to Buy at 35.94 (stop at 32.00)
Posted a Bullish Hammer Bottom on the Daily chart. Although the anticipated move higher is corrective, it does offer ample risk/reward today. We therefore, prefer to fade into the dip with a tight stop in anticipation of a move back higher. Expect trading to remain mixed and volatile.
Our profit targets will be 49.43 and 60.00
Resistance: 45.00 / 63.00 / 76.00
Support: 35.00 / 23.12 / 15.00
Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NVAX Long -- Good ER expectation A small pull back to retest $56/57 pivot high, then spike towards $72/80.
Next quarter expectation should be good.
Novavax Breaking Out? Novavax - Short Term - We look to Buy at 83.80 (stop at 75.92)
Price action has posted a bullish Engulfing Candle and is positive for short-term sentiment. We look for gains to be extended today. Short term oscillators have turned positive. Although the bears are in control, the stalling negative momentum indicates a turnaround is possible.
Our profit targets will be 101.48 and 112.00
Resistance: 90.00 / 100.00 / 140.00
Support: 70.00 / 60.00 / 50.00
Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NOVAVAX Fractal and Symmetric trianglefirst of all thanks for stopping by.. This text below will be posted on every timeframe
Until now, not much was known about Novavax because it was Moderna or Pfizer what was on the news and media, but now NOVAVAX has been in the news and so that's why the chart popped up on my radar .
On the big picture I'm looking at the 2 monthly chart
To remove some noise and get a good idea of the price, I find a DRABW Right Angled Descending Broadening Wedge here, often a Bullish pattern . At the top we see that another support line has been found where the bulls can prepare themself to make an attempt to attack the upper resistance / ATH again. see also in this picture the divergence that has managed to make a considerable run up. Here it is also nice to see how the share price reacts to favorable news for a company like this.
To stay in the even number, we zoom in slightly to the 2W chart.
here we see very nicely how a Bump and Run is rejected on the 0.382 of the fibonacci, the price just looks up the trend channel and from there the bulls make another attack on the resistance line (Lead-in) and with succes. So mirroring the pattern could give an idea for where it could go .. and so we have now ended up in a symmetrical triangle i even think that in an EW count, this could be an Ending diagonal or a correction wave. and after a corrective wave comes another impulse wave (up or down).
Ending with the day chart. zoomed in on the symmetrical triangle.
good to see how the pressure is on the top in the pattern. and the picture is how the situation is. you could even spot a fractal white squares and if it would continue, which means that it could happen again. So keep an eye out and look for supporting within the pattern.
Keep calm, do your own research! trade safe and manage your risk.
*(Disclaimer: This is not financial advice)
NOVAVAX BARR into Symmetric trainglefirst of all thanks for stopping by.. This text below will be posted on every timeframe
Until now, not much was known about Novavax because it was Moderna or Pfizer what was on the news and media, but now NOVAVAX has been in the news and so that's why the chart popped up on my radar .
On the big picture I'm looking at the 2 monthly chart
To remove some noise and get a good idea of the price, I find a DRABW Right Angled Descending Broadening Wedge here, often a Bullish pattern . At the top we see that another support line has been found where the bulls can prepare themself to make an attempt to attack the upper resistance / ATH again. see also in this picture the divergence that has managed to make a considerable run up. Here it is also nice to see how the share price reacts to favorable news for a company like this.
To stay in the even number, we zoom in slightly to the 2W chart.
here we see very nicely how a Bump and Run is rejected on the 0.382 of the fibonacci, the price just looks up the trend channel and from there the bulls make another attack on the resistance line (Lead-in) and with succes. So mirroring the pattern could give an idea for where it could go .. and so we have now ended up in a symmetrical triangle i even think that in an EW count, this could be an Ending diagonal or a correction wave. and after a corrective wave comes another impulse wave (up or down).
Ending with the day chart. zoomed in on the symmetrical triangle.
good to see how the pressure is on the top in the pattern. and the picture is how the situation is. you could even spot a fractal white squares and if it would continue, which means that it could happen again. So keep an eye out and look for supporting within the pattern.
Keep calm, do your own research! trade safe and manage your risk.
*(Disclaimer: This is not financial advice)
NOVAVAX DRABW first of all thanks for stopping by.. This text below will be posted on every timeframe
Until now, not much was known about Novavax because it was Moderna or Pfizer what was on the news and media, but now NOVAVAX has been in the news and so that's why the chart popped up on my radar .
On the big picture I'm looking at the 2 monthly chart
To remove some noise and get a good idea of the price, I find a DRABW Right Angled Descending Broadening Wedge here, often a Bullish pattern . At the top we see that another support line has been found where the bulls can prepare themself to make an attempt to attack the upper resistance / ATH again. see also in this picture the divergence that has managed to make a considerable run up. Here it is also nice to see how the share price reacts to favorable news for a company like this.
To stay in the even number, we zoom in slightly to the 2W chart.
here we see very nicely how a Bump and Run is rejected on the 0.382 of the fibonacci, the price just looks up the trend channel and from there the bulls make another attack on the resistance line (Lead-in) and with succes. So mirroring the pattern could give an idea for where it could go .. and so we have now ended up in a symmetrical triangle i even think that in an EW count, this could be an Ending diagonal or a correction wave. and after a corrective wave comes another impulse wave (up or down).
Ending with the day chart. zoomed in on the symmetrical triangle.
good to see how the pressure is on the top in the pattern. and the picture is how the situation is. you could even spot a fractal white squares and if it would continue, which means that it could happen again. So keep an eye out and look for supporting within the pattern.
Keep calm, do your own research! trade safe and manage your risk.
*(Disclaimer: This is not financial advice)
NVAX Analysis - Bulls in ControlSimilarities can be seen in red,yellow,green
The breakabove the fib circle level, which has previously been seen as a strong resistance point is an extremely good sign
along with the possible development of a vaccine for a new variant (if the current vaccine isn't effective)
NVAX looks bullish
Novavax ShortPfizer's monopoly is very strong on the Covid-19 vaccines . They are spending millions hiding their side effects and creating hurdles for their competitors at the regulatory agencies SUCCESSFULLY . It maybe that Novavax has one the best products out there but that simply does not matter at this point , we know how powerful big pharma can be and Novavax's lateness to the game will not serve them well here . The biggest dangers to NVAX are now the regulatory agencies taking long/asking for additional info and the COVID-19 Antiviral drug news ( Merck's pill approval will be this months and Pfizer may come out with their Phase III study result any moment now). Both are very likely .
NVAX will likely reject braking $200 TODAY. $195 -$200 will be a great entry point for a opening a short position on this . RISK /REWARD RATIO VERY LUCRATIVE .
NVAX Short Novavax will issue a statement ahead of their upcoming earnings in a couple of weeks that they have scrapped the plans for a Covid-19 vaccine and now instead they are working on a Covid-flu combo for the next year . The insiders and the main hedge fund manager Peter Kolchinsky have already shorted the stock last week . I fully expect It will be anywhere between $40-$77 in three weeks time . Good luck !
$NVAX idea based on fractals$NVAX idea based on fractals
In the near future I expect to see a sideways trend, a decline in volumes and an explosive growth after all.
NVAX Novavax Analyst RatingsOn 6/15/2021 Cantor Fitzgerald brokerage Boosted the Price Target from Reduce to Overweight $217.00 to $272.00
On 5/18/2021 JPMorgan Chase & Co. brokerage Reiterated Rating from Overweight to Neutral $285.00 to $161.00
On 5/12/2021 B. Riley brokerage Lowered the Price Target from $365.00 to $286.00
On 5/12/2021 HC Wainwright brokerage Lowered the Price Target from $317.00 to $294.00
My personal price target is $240.
Looking forward to read your opinion.
NVAX coming back 400+ soonHey guys so NVAX had a nice bounce today from its open at 240 and closed at 273.98. It was a solid day I'm not too happy about the volume though due to it being pretty low. The stock is not going to have a tremendous move if there is no volume. We need to have above average volume to see a nice spike above 300 again. Now with the EU news coming possibly end of this week or next week I believe NVAX is going to skyrocket. I am still staying strong with my bullish target of 400 by end of February due to the amount of volume and buy orders we are going to have with the incredible EU deal. Even if EU does not come out this week we still are very oversold on the indicators and have destroyed Pfizer’s new SA variant numbers which show only 20% effectiveness on the new variant. Ours is 60% if you forgot, so we are in good shape right now do not be intimidated by shorts and hold strong!!
This is what I see for NVAX for 2021 huge gains are coming inNVAX stock has had a massive explosion from January where the stock hit 294 a share yesterday. Now I had a prediction that NVAX would break 300 a share by March I think it will be much sooner now. With all the orders and revenue stream that will be produced in 2021, we could see total revenue of 16 billion dollars. I am firmly confident we can reach the same market cap as Moderna as our vaccine is currently more effective and we have more vaccine orders. You may think I am crazy when I predict 1200 a share in a year but if you do the math and see the data it becomes quite convincing. I am not gonna even think about selling until this stock reaches over 500 which I believe could come in May.
